Update on catatonia

Psychiatric Times

Volumn 23, Issue 9, 2006, Pages 85-86

  Francis, Andrew ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845792522     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Kahlbaum KL. Catatonia. Levi Y, Pridon T, trans. Baltimore, Md: Johns Hopkins University Press; 1973.
2. Caroff S, Mann S, Campbell E, Sullivan K. Epidemiology. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:15-32.
3. Abrams R, Taylor MA. Catatonia: a prospective clinical study. Arch Gen Psych. 1976;33:579-581.
4. Barnes MP, Saunders M, Walls TJ, et al. The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatr. 1986;49:991-996.
5. Gelenberg AJ. The catatonic syndrome. Lancet. 1976;2:1339-1341.
6. Wilcox JA, Nasrallah HA. Organic factors in catatonia. Br J Psychiatry. 1986;149:782-784.
7. Benegal V, Hingorani S, Khanna S. Idiopathic catatonia: validity of the concept. Psychopathology. 1993;26:41-46.
8. Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry. 2003;160:1233-1241.
9. White DA. Catatonia and the neuroleptic malignant syndrome-a single entity? Br J Psychiatry. 1992;161:558-560.
10. Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge, UK: Cambridge Press; 2003.
11. Koch M, Chandragiri S, Rizvi S, et al. Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry. 2000;41:73-75.
12. Francis A, Chandragiri S, Rizvi S, et al. Is lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectr. 2000;5:54-57.
13. Khaldarov V. Benzodiazepines as a treatment for neuroleptic malignant syndrome. Hosp Physician. 2000;6:51-55.
14. Petrides G, Divadeenam KM, Bush G, Francis A. Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia. Biol Psychiatry. 1997;42:375-381.
15. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatr Res. 2005;135:249-256.
16. Yacoub A, Francis A. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr Dis Treat. In press.
17. Bush G, Petrides G, Francis A. Catatonia and other motor syndromes in a chronically hospitalized psychiatric population. Schizophr Res. 1997;27:83-92.
18. Starkstein SE, Petracca G, Teson A, et al. Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J Neurol Neurosurg Psychiatry. 1996;60:326-332.
19. Bush G, Fink M, Petrides G, et al. Catatonia I: rating scale and standardized examination. Acta Psychiatr Scand. 1996;93:129-136.
20. Bush G, Fink M, Petrides G, et al. Catatonia II: treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;93:137-143.
21. Northoff G, Koch A, Wenke A, et al. Catatonia as a psychomotor syndrome: a rating scale and extrapyramidal motor symptoms. Mov Disord. 1999;14:404-416.
22. Girish K, Gill NS. Electro convulsive therapy in lorazepam non-responsive catatonia. Indian J Psychiatry. 2003;45:21-25.
23. Lund CE, Mortimer AM, McKenna PJ. Motor, volitional and behavioural disorders in schizophrenia. 1: assessment using the Modified Rogers Scale. Br J Psychiatry. 1991;158:323-327.
24. Bräunig P, Kruger S, Shugar G, et al. The catatonia rating scale I-development, reliability, and use. Compr Psychiatry. 2000;41:147-158.
25. Carroll BT, Kennedy JC, Goforth HW. Catatonic signs in medical and psychiatric catatonias. CNS Spectr. 2000;5:66-69.
26. Lopez-Canino A, Francis A. Drug-induced catatonia. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:129-140.
27. Taylor MA, Catatonia: a review of a behavioral neurologic syndrome. Neuropsychiat Neuropsychol Behav Neurol. 1990;3:48-72.
28. Carroll BT, Goforth HW. Medical catatonia. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004: 121-128.
29. Stöber G. Genetics. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:173-188.
30. Northoff G. Neuroimaging and neurophysiology. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004: 77-92.
31. Carroll BT. GABAa versus GABAb hypothesis of catatonia. Mov Disord. 1999;14:702-703.
32. McCall WV, Shelp FE, McDonald WM. Controlled investigation of the amobarbital interview for catatonic mutism. Am J Psychiatry. 1992;149:202-206.
33. Rosebush P, Mazurek M. Pharmacotherapy. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:141-150.
34. Wetzel H, Heuser I, Benkert O. Stupor and affective state: alleviation of psychomotor disturbances by lorazepam and recurrence of symptoms after Ro 15-1788. J Nerv Ment Dis. 1987;175:240-242.
35. Lee JWY, Schwartz DI, Hallmayer J. Catatonia in a psychiatric intensive care facility: incidence and response to benzodiazepines. Ann Clin Psychiatry. 2000;12:89-96.
36. Rosebush PL, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990;51:357-362.
37. Ungvari GS, Chiu HFK, Chow LY, et al. Lorazepam for chronic catatonia: a randomized double-blind, placebo-controlled cross-over study. Psychopharmacology (Berl). 1999;142:393-398.
38. Petrides G, Malur C, Fink M. Convulsive therapy. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:151-160.
39. White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991;158:419-421.
40. Hawkins JM, Archer KJ, Strakowski SM, Keck PE. Somatic treatment of catatonia. Int J Psychiatry Med. 1995;25:354-369.
41. Bahro M, Kampf C, Strnad J. Catatonia under medication with risperidone in a 61-year-old patient. Acta Psychiatr Scand. 1999;99:223-224.
42. Carroll BT. The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectr. 2000;5:26-33.
43. White DAC, Robins AH. An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. CNS Spectr. 2000;5:58-65.
44. Van Den Eede F, Van Hecke J, Van Dalfsen A, et al. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry. 2005;20:422-429.
45. Martenyi F, Metcalfe S, Schausberer B, Dossenbach MR. An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. J Clin Psychiatry. 2001;62(suppl 2):25-27.
46. Mann SC, Caroff SN, Fricchione GL, et al. Malignant catatonia. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:105-120.